Immix Biopharma, Inc. IMMX Other Accounts Payable and Accrued Liabilities
Other Accounts Payable and Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccountsPayableAndAccruedLiabilities.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s other accounts payable and accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s other accounts payable and accrued liabilities?
- Immix Biopharma, Inc. (IMMX) reported other accounts payable and accrued liabilities of $193.72K in Q1 2026.
- How has Immix Biopharma, Inc.'s other accounts payable and accrued liabilities changed year-over-year?
- Immix Biopharma, Inc.'s other accounts payable and accrued liabilities increased by 52.1% year-over-year, from $127.37K to $193.72K.
- What is the long-term trend for Immix Biopharma, Inc.'s other accounts payable and accrued liabilities?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s other accounts payable and accrued liabilities has grown at a -8.9% compound annual growth rate (CAGR), from $438.2K to $331.8K.